|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PACRGL |
Gene summary for PACRGL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PACRGL | Gene ID | 133015 |
| Gene name | parkin coregulated like | |
| Gene Alias | C4orf28 | |
| Cytomap | 4p15.31 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8N7B6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 133015 | PACRGL | LZE24T | Human | Esophagus | ESCC | 3.32e-06 | 1.71e-01 | 0.0596 |
| 133015 | PACRGL | P1T-E | Human | Esophagus | ESCC | 9.49e-06 | 2.18e-01 | 0.0875 |
| 133015 | PACRGL | P2T-E | Human | Esophagus | ESCC | 1.85e-18 | 2.67e-01 | 0.1177 |
| 133015 | PACRGL | P4T-E | Human | Esophagus | ESCC | 4.32e-04 | 1.49e-01 | 0.1323 |
| 133015 | PACRGL | P8T-E | Human | Esophagus | ESCC | 9.56e-11 | 1.66e-01 | 0.0889 |
| 133015 | PACRGL | P9T-E | Human | Esophagus | ESCC | 1.56e-04 | 8.06e-02 | 0.1131 |
| 133015 | PACRGL | P10T-E | Human | Esophagus | ESCC | 3.59e-10 | 1.60e-01 | 0.116 |
| 133015 | PACRGL | P12T-E | Human | Esophagus | ESCC | 8.72e-10 | 1.19e-01 | 0.1122 |
| 133015 | PACRGL | P15T-E | Human | Esophagus | ESCC | 3.46e-04 | 6.39e-02 | 0.1149 |
| 133015 | PACRGL | P16T-E | Human | Esophagus | ESCC | 1.58e-16 | 2.72e-01 | 0.1153 |
| 133015 | PACRGL | P20T-E | Human | Esophagus | ESCC | 6.12e-03 | 1.11e-01 | 0.1124 |
| 133015 | PACRGL | P21T-E | Human | Esophagus | ESCC | 2.76e-21 | 4.28e-01 | 0.1617 |
| 133015 | PACRGL | P22T-E | Human | Esophagus | ESCC | 2.31e-02 | 6.54e-02 | 0.1236 |
| 133015 | PACRGL | P23T-E | Human | Esophagus | ESCC | 9.74e-07 | 1.44e-01 | 0.108 |
| 133015 | PACRGL | P24T-E | Human | Esophagus | ESCC | 1.96e-08 | 1.34e-01 | 0.1287 |
| 133015 | PACRGL | P27T-E | Human | Esophagus | ESCC | 1.34e-03 | 1.25e-01 | 0.1055 |
| 133015 | PACRGL | P28T-E | Human | Esophagus | ESCC | 3.49e-06 | 5.89e-02 | 0.1149 |
| 133015 | PACRGL | P30T-E | Human | Esophagus | ESCC | 9.48e-09 | 2.14e-01 | 0.137 |
| 133015 | PACRGL | P31T-E | Human | Esophagus | ESCC | 4.53e-15 | 1.47e-01 | 0.1251 |
| 133015 | PACRGL | P32T-E | Human | Esophagus | ESCC | 1.02e-04 | 1.73e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PACRGL | deletion | Frame_Shift_Del | novel | c.37delN | p.Asn14ThrfsTer17 | p.N14Tfs*17 | Q8N7B6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PACRGL | SNV | Missense_Mutation | c.569N>C | p.Gly190Ala | p.G190A | Q8N7B6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PACRGL | SNV | Missense_Mutation | c.517N>A | p.Glu173Lys | p.E173K | Q8N7B6 | protein_coding | tolerated(0.17) | benign(0.033) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PACRGL | SNV | Missense_Mutation | c.545T>C | p.Leu182Pro | p.L182P | Q8N7B6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| PACRGL | SNV | Missense_Mutation | c.278N>C | p.Leu93Ser | p.L93S | Q8N7B6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PACRGL | SNV | Missense_Mutation | rs576654808 | c.583G>A | p.Asp195Asn | p.D195N | Q8N7B6 | protein_coding | tolerated(0.3) | benign(0.115) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PACRGL | SNV | Missense_Mutation | novel | c.634N>C | p.Lys212Gln | p.K212Q | Q8N7B6 | protein_coding | tolerated(0.25) | benign(0.146) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| PACRGL | SNV | Missense_Mutation | c.374G>T | p.Arg125Ile | p.R125I | Q8N7B6 | protein_coding | tolerated(0.06) | benign(0.268) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PACRGL | SNV | Missense_Mutation | novel | c.691N>A | p.Gly231Arg | p.G231R | Q8N7B6 | protein_coding | tolerated(0.08) | benign(0.295) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PACRGL | SNV | Missense_Mutation | novel | c.299A>G | p.His100Arg | p.H100R | Q8N7B6 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |